315 Cambridge Science Park,
Cambridge, CB4 0WG
+44 1223 226900
Domantis has pioneered the next generation of antibody therapy, which is based on the smallest functional binding units of human antibodies. These units, termed domain antibodies (dAbs), may be administered in inhaled, topical, and, potentially, oral formulations as well as by injection and infusion. The Domantis technology also enables dAbs to serve as building blocks for therapeutics simultaneously directed at more than one disease target.
Domantis was acquired by GlaxoSmithKline on December 08, 2006.
Join Mergr to view all 120 acquisitions of life science companies in 2006, including 22 acquisitions by private equity firms, and 98 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2006. The largest life science acquisition in 2006 was Guidant - which was acquired by Boston Scientific for $24.6B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Domantis.
No obligation. Cancel anytime.